UBS Maintains Buy on CVS Health, Raises Price Target to $100

Benzinga Newsdesk www.benzinga.com Positive 71.8%

Neg 0% Neu 0% Pos 71.8%

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $97 to $100.

Comments

No comments yet. Be the first!